HealthDay News — For pediatric and adolescent oncology patients, a single-dose 13-valent pneumococcal conjugate vaccine (PCV13) is safe and immunogenic, according to a study published in Cancer.
Te-Yu Hung, MBBS, from the Princess Margaret Hospital for Children in Perth, Australia, and colleagues conducted a prospective, open-label cohort study involving 85 children ages 1 to 18 years receiving active immunosuppressive therapy (AIT) or within 12 months after completing immunosuppressive therapy (CIT) for cancer. Blood was sampled before and 4 weeks after administration of single-dose PCV13; side effects were recorded after vaccination.
The researchers found that ≤50% had protective antibody titers against Streptococcus pneumoniae for 10 and 8 serotypes, respectively, in the AIT and CIT groups at baseline.
After vaccination, in the AIT and CIT groups, ≥70% had protective antibody titers for 9 and 11 serotypes, respectively. Comparable responses to PCV7 serotypes were seen for both groups, whereas a significantly higher proportion of patients in the CIT group achieved protective antibody titers to PCV13. The rate of serious adverse events was low (3.5%).
“The current data support the recommendation for an additional dose of PCV13 after the completion of immunosuppressive therapy to provide additional protection against invasive pneumococcal disease,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Hung TY, Kotecha RS, Blyth CC, et al. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients [published online July 11, 2017]. Cancer. doi: 10.1002/cncr.30764.